earticle

영어

Dengue hemorrhage fever is one of the most serious and recurrent epidemics in tropical countries. Hitherto there has not been a commercially available vaccine against this virus. This is because there are four similar but not identical serotypes and an effective vaccine must be able to neutralize all serotypes simultaneously. Recently a potential neutralizing epitope, namely the domain III of envelop protein, has been identified and several proof-of-concepts have been established for this particular antigen. In this study we attempt to develop an oral vaccine against the serotype 2 by expressing this antigen in fusion with Heat Labile Toxin (LTB) protein from E.coli in Saccharomyces cerevisiae. The protein was expressed in both secretory form and intracellular form. Success of the expression was determined by Western blotting and GM1 ELISA. Optimization for protein expression was also attempted. Finally the product is intended to be tested on mice to determine the efficacy of this vaccine against dengue virus serotype 2.